>
The Self-Sufficiency Myth No One Talks About
We Investigated The Maui Fires and The Cover-Up is Worse Than We Thought | Redacted
The Amish Secret to Keeping Pests Out of Your Garden Forever
Scott Ritter: Full-Scale War as Iran Attacks All U.S. Targets
US particle accelerators turn nuclear waste into electricity, cut radioactive life by 99.7%
Blast Them: A Rutgers Scientist Uses Lasers to Kill Weeds
H100 GPUs that cost $40,000 new are now selling for around $6,000 on eBay, an 85% drop.
We finally know exactly why spider silk is stronger than steel.
She ran out of options at 12. Then her own cells came back to save her.
A cardiovascular revolution is silently unfolding in cardiac intervention labs.
DARPA chooses two to develop insect-size robots for complex jobs like disaster relief...
Multimaterial 3D printer builds fully functional electric motor from scratch in hours
WindRunner: The largest cargo aircraft ever to be built, capable of carrying six Chinooks

3 patients experienced complete remission after regularly taking fenbendazole.
But the cancer industry seems to hate it because it only costs about $11 per week.
Fenbendazole (FBZ) is a medicine originally designed to treat worms and parasites in animals. Its sister drugs, Mebendazole and Albendazole, have had remarkable success treating similar ailments in humans with few side effects.
The case series highlights the remarkable stories of three cancer patients who achieved miraculous recoveries with fenbendazole after exhausting all conventional therapies.
After analyzing these cases, the abstract concluded, "FBZ appears to be a potentially safe and effective antineoplastic agent that can be repurposed for human use in treating genitourinary malignancies."
Adding to the growing evidence in support of fendendazole's use case against cancer, an Oklahoma man credited his miraculous cancer recovery to the pet med after overcoming terminal small cell lung cancer, defying a less than 1% survival rate and leaving doctors baffled.
This story is truly remarkable. Watch.